Company / Working Capital
ELITE PHARMACEUTICALS INC /NV/ Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$45.9M
FY2025
5-year range
$6.4M / $45.9M
FY2021-FY2025
Trend
+70.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has increased for 5 consecutive years, from $2M in FY2020 to $46M in FY2025.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of +95.4%.
Improved from $14M to $46M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +55.7%
- 5-Year CAGR
- +95.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- ELITE PHARMACEUTICALS INC /NV/'s working capital has grown for 5 consecutive years.
- 5-year CAGR of +95.4%, indicating consistent growth.
- In FY2025, working capital increased 70.2% year-over-year.
- Lowest working capital in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.9M | +70.2% |
| FY2024 | $27.0M | +97.2% |
| FY2023 | $13.7M | +12.4% |
| FY2022 | $12.2M | +90.6% |
| FY2021 | $6.4M | +296.0% |
| FY2020 | $1.6M | -17.4% |
| FY2019 | $2.0M | -77.3% |
| FY2018 | $8.6M | -43.0% |
| FY2017 | $15.1M | +24.8% |
| FY2016 | $12.1M | +66.3% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026